2-Isopropyl-1,3-chlorhydrin | 36381-74-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Isopropyl-1,3-chlorhydrin
• 英文别名: 2-chloromethyl-3-methyl-butan-1-ol；2-(Chloromethyl)-3-methylbutan-1-ol
• CAS: 36381-74-5
• 化学式: C₆H₁₃ClO
• mdl: MFCD19234973
• 分子量: 136.622
• InChiKey: DJYFIOSZSYOHFT-UHFFFAOYSA-N

物化性质

• 沸点：
  199.0±13.0 °C(Predicted)
• 密度：
  0.995±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• PROTEIN KINASE INHIBITORS
  申请人：Pharmascience, Inc.

  公开号：US20150191473A1

  公开（公告）日：2015-07-09

  The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.

  本发明涉及一种新型的蛋白激酶抑制剂家族。具体而言，本发明涉及Tec和Src蛋白激酶家族成员的抑制剂。
• Compounds useful as kinase inhibitors
  申请人：Loxo Oncology, Inc.

  公开号：US10464905B2

  公开（公告）日：2019-11-05

  This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

  本发明涉及新型化合物。本发明的化合物是酪氨酸激酶抑制剂。具体来说，本发明的化合物可用作布鲁顿酪氨酸激酶（BTK）的抑制剂。本发明还考虑将这些化合物用于治疗可通过抑制布鲁顿酪氨酸激酶治疗的疾病，例如癌症、淋巴瘤、白血病和免疫性疾病。
• IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160304524A1

  公开（公告）日：2016-10-20

  Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
• COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：Loxo Oncology, Inc.

  公开号：US20190000806A1

  公开（公告）日：2019-01-03

  This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
• US9796716B2
  申请人：——

  公开号：US9796716B2

  公开（公告）日：2017-10-24